M&A / Deals Daiichi Sankyo and Waiv partner for ADC biomarkers Pharmaceutical TechnologyDaiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.OncologyRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) Pharmaceutical Technology Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme. Oncology Read full story Post navigation Previous: Halozyme and Oruka sign agreement for Hypercon technologyNext: Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
